VERA
Vera Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$34.00
−0.79%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$34.56
From 52W high−38.93%
Volume4.19M
Market cap$2.45B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$34.56
From 52W high
−38.93%
Volume
4.19M
Market cap
$2.45B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−5.2x
P/E (TTM)
—
RSI (14)
50.0
MomentumView details →
1D Return
−0.79%
YTD Return
−32.84%
SummaryUpdated Jun 1, 2026
Vera Therapeutics, Inc. (NASDAQ:VERA) is a clinical-stage biotechnology company founded in 2016 and headquartered in Brisbane, California. Originally incorporated as Trucode Gene Repair, Inc., the company changed its name to Vera Therapeutics in April 2020 and went public in May 2021. The company focuses on developing and commercializing treatments for patients with serious immunological diseases, with its primary emphasis on rare kidney diseases and viral infections that affect immunocompromised patients.
Similar companies
Latest newsMore news →
Vera Therapeutics announced data from the ORIGIN 3 trial, sending its shares lower after an initial spike.5d agoVera Therapeutics announced positive final efficacy results from the Phase 3 ORIGIN 3 trial of its kidney disease drug tortacna in adults with primary IgA nephropathy, meeting all pre-specified endpoints.5d agoVera Therapeutics reported final two-year Phase 3 results showing its drug Trutakna stabilized kidney function and reduced kidney-related death and complications in patients with chronic autoimmune kidney disease, and said it will seek full FDA approval in the fourth quarter.5d ago